PGEN
NASDAQ · Biotechnology
Precigen Inc
$5.56
+0.16 (+2.96%)
Financial Highlights (FY 2026)
Revenue
11.02M
Net Income
-285,493,972
Gross Margin
50.2%
Profit Margin
-2,588.2%
Rev Growth
-28.9%
D/E Ratio
4.46
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 50.2% | 50.2% | 42.3% | 42.3% |
| Operating Margin | -1,141.1% | -1,027.0% | -7.4% | -9.4% |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% | -8.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 11.02M | 15.49M | 411.38M | 421.12M |
| Gross Profit | 5.53M | 7.77M | 173.84M | 177.96M |
| Operating Income | -125,709,026 | -159,035,877 | -30,534,477 | -39,472,830 |
| Net Income | -285,493,972 | -361,181,578 | -34,816,902 | -35,997,358 |
| Gross Margin | 50.2% | 50.2% | 42.3% | 42.3% |
| Operating Margin | -1,141.1% | -1,027.0% | -7.4% | -9.4% |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% | -8.6% |
| Rev Growth | -28.9% | -28.9% | +17.8% | -9.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 701.71M | 701.71M | 657.59M | 697.63M |
| Total Equity | 157.49M | 157.49M | 694.85M | 748.63M |
| D/E Ratio | 4.46 | 4.46 | 0.95 | 0.93 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -122,247,606 | -163,248,841 | -49,679,638 | -48,292,540 |
| Free Cash Flow | — | — | -21,385,787 | -28,685,035 |